The World Health Organization has declared a public health emergency due to a rare strain of Ebola known as Bundibugyo, primarily affecting the Democratic Republic of the Congo and Uganda. As of Monday, there are over 100 suspected deaths and nearly 400 suspected infections. Bundibugyo, named after Uganda's Bundibugyo province where it was first identified in 2007-2008, has a fatality rate of 30% to 40%, significantly lower than the 90% for the more common Zaire strain. Unlike Zaire, Bundibugyo replicates more slowly and has less severe long-term effects on the liver and kidneys. Currently, there are no approved vaccines or treatments for Bundibugyo, but potential candidates are being investigated, including Merck’s Ervebo and an experimental antiviral drug NV-387. Public health measures such as rapid case detection, isolation, and community engagement are crucial for controlling the outbreak. Testing for Bundibugyo exists but has faced challenges, leading to delays in response due to initial false negatives. Experts emphasize the importance of effective public health strategies to manage and contain this outbreak.